Cost utility of a pharmacist‑led minor ailment service compared with usual pharmacist care by Benrimoj, Shalom Isaac & Dineen Grifn, Sarah
Dineen‑Griffin et al. Cost Eff Resour Alloc           (2020) 18:24  
https://doi.org/10.1186/s12962‑020‑00220‑0
RESEARCH
Cost utility of a pharmacist‑led minor 
ailment service compared with usual 
pharmacist care
Sarah Dineen‑Griffin1* , Constanza Vargas2 , Kylie A. Williams1 , Shalom I. Benrimoj3  
and Victoria Garcia‑Cardenas1 
Abstract 
Background: A cluster randomised controlled trial (cRCT) performed from July 2018 to March 2019 demonstrated 
the clinical impact of a community pharmacist delivered minor ailment service (MAS) compared with usual phar‑
macist care (UC). MAS consisted of a technology‑based face‑to‑face consultation delivered by trained community 
pharmacists. The consultation was guided by clinical pathways for assessment and management, and communica‑
tion systems, collaboratively agreed with general practitioners. MAS pharmacists were trained and provided monthly 
practice support by a practice change facilitator. The objective of this study was to assess the cost utility of MAS, 
compared to UC.
Methods: Participants recruited were adult patients with symptoms suggestive of a minor ailment condition, from 
community pharmacies located in Western Sydney. Patients received MAS (intervention) or UC (control) and were 
followed‑up by telephone 14‑days following consultation with the pharmacist. A cost utility analysis was conducted 
alongside the cRCT. Transition probabilities and costs were directly derived from cRCT study data. Utility values were 
not available from the cRCT, hence we relied on utility values reported in the published literature which were used to 
calculate quality adjusted life years (QALYs), using the area under the curve method. A decision tree model was used 
to capture the decision problem, considering a societal perspective and a 14‑day time horizon. Deterministic and 
probabilistic sensitivity analyses assessed robustness and uncertainty of results, respectively.
Results: Patients (n = 894) were recruited from 30 pharmacies and 82% (n = 732) responded to follow‑up. On aver‑
age, MAS was more costly but also more effective (in terms of symptom resolution and QALY gains) compared to UC. 
MAS patients (n = 524) gained an additional 0.003 QALYs at an incremental cost of $7.14 (Australian dollars), com‑
pared to UC (n = 370) which resulted in an ICER of $2277 (95% CI $681.49–3811.22) per QALY.
Conclusion: Economic findings suggest that implementation of MAS within the Australian context is cost effective.
Trial registration Registered with Australian New Zealand Clinical Trials Registry (ANZCTR) and allocated the ACTRN: 
ACTRN12618000286246. Registered on 23 February 2018.
Keywords: Cost utility, Cost effectiveness, Minor ailment services, Self‑care, Community pharmacy, Community 
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Background
Minor ailment presentations to emergency depart-
ments (EDs) and general practitioners (GPs) for con-
ditions such as headaches, coughs, colds and earaches 
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are an inefficient use of public resources [1]. Minor ail-
ments have been defined in the literature as “self-limiting 
or uncomplicated conditions that can be diagnosed and 
managed without medical (i.e. GP) intervention” [2–4]. 
Self-care is the preferred method of managing minor 
ailments for many patients [5]. A 2019 policy statement 
from the International Pharmaceutical Federation and 
the Global Self-Care Federation, described the intention 
of the pharmacy profession to facilitate self-care and fur-
ther develop self-care as a “pillar of sustainable health 
systems” [6, 7]. This statement supports pharmacists to 
encourage consumers to use health system resources 
responsibly and engage in self-care when appropriate [6, 
7].
Internationally, governments have been investing in 
supporting pharmacies to enhance self-care and self-
medication practices [8–10]. Health policies have been 
developed in a number of countries to encourage self-
care at the community pharmacy level. This is probably 
due to increases in GP and ED presentations, which has 
led governments to review policy to support self-care 
[10–15]. Minor ailment services (MASs) in the United 
Kingdom (UK) and pharmacists prescribing for  minor 
ailment (PPMA) services in Canada have been imple-
mented in community pharmacies [16]. Other countries, 
such as Spain [17], New Zealand [18] and Ireland [19] are 
evaluating the feasibility of similar initiatives.
Several arguments or reasons have been proposed for 
the development of health policies encouraging health 
systems to incorporate this type of services, some being 
focused on reducing the load/number of visits to general 
practice and emergency settings. Others have focused on 
the economic aspects of transferring the management 
of minor ailments to the community pharmacy setting. 
In this regard, there are a number of economic stud-
ies published in the literature focusing on community 
pharmacist management of minor ailments in the UK 
and Canada [3, 16, 20–27]. In the UK Watson et al. esti-
mated the cost and health outcomes of pharmacy-based 
care of minor ailments compared with care provided in 
general practice and ED settings, using a prospective 
cohort study design [25]. Mean overall costs per consul-
tation were £29.30 for pharmacy care, when compared 
with general practice (£82.34) and ED (£147.09) [25]. As 
pharmacy was estimated to be less costly and as effective 
(in terms of symptom resolution) compared with ED and 
general practice, it was said to dominate both of these 
options [25]. Similarly, Rafferty et al. conducted an eco-
nomic impact analysis measuring the costs of pharma-
cists prescribing for minor ailments, and the alternative 
scenario of usual care in Canada [16]. These studies show 
a positive economic impact through reduced costs asso-
ciated with the unnecessary use of other more expensive 
health services and settings for the management of minor 
ailment presentations [25]. Although the international 
literature is positive, application of MAS to the Austral-
ian health system requires local data to ensure transfer-
ability. No economic evaluations have been conducted 
to date using local data of a community pharmacist-
delivered service (MAS) compared with usual pharmacist 
care (UC), which represents current practice in Australia. 
This would allow a better understanding on the costs and 
outcomes associated to this intervention and ultimately 
assess if MAS represents a value for money intervention 
in the Australian setting.
Methods
Economic analysis description
The economic evaluation consisted of a cost utility analy-
sis (CUA) (Table  1). Direct health care costs affecting 
both, the health care system and the patient through out 
of pocket costs, were included in the analysis. Although 
broader cost implications to the society (e.g. indirect 
costs) were not taken into consideration, the perspective 
was considered as a societal as some of the direct health 
care costs were borne by actors outside of the health 
care system, the patient [28]. By definition, a minor ail-
ment is a self-limiting problem and implicitly involves 
resolution regardless of the intervention performed by 
the pharmacist [29]. A time horizon of 14 days was con-
sidered appropriate to account for costs and health out-
comes given minor ailments are generally time limiting 
and would resolve in this time frame. A 14-day time hori-
zon has been previously applied in international studies 
assessing minor ailments and symptom resolution [25]. 
Furthermore, the time frame was pragmatically chosen 
by researchers to reduce the possibility of recall bias [30]. 
Costs were measured in 2018 Australian dollars (AUD) 
and health outcomes were measured in quality adjusted 
life years (QALYs). Deterministic and probabilistic 
Table 1 Components of the economic evaluation
CUA cost utility analysis, QALY quality adjusted life years
Types of analysis CUA 
Intervention Pharmacist‑led minor ailment service (or MAS)
Comparator Usual pharmacist care (or UC)
Outcomes QALY
Episode of appropriate pharmacist care
Extra patient achieving symptom resolution
Perspective Societal
Time horizon 14 days
Method used to gener‑
ate results
Decision tree
Software Microsoft Excel for Mac Version 16.16.10
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sensitivity analyses were also conducted to account for 
robustness and uncertainty of the results. The analyses’ 
are reported according to the Consolidated Health Eco-
nomic Evaluation Reporting Standards checklist [31].
Decision tree model
A decision analytic modelling technique was employed 
for the economic evaluation which consisted of a deci-
sion tree implemented in Microsoft Excel for Mac Ver-
sion 16.16.10 (Fig. 1). A decision tree was considered the 
most adequate modelling technique because the decision 
problem surrounding minor ailments is relatively simple 
and straight forward (a once-only disease event); a lim-
ited number of health states were identified as relevant; 
the short model duration; and the fixed time horizon 
was pre-specified. As depicted in Fig.  1, the two  strat-
egies (MAS and UC) are denoted by each branch from 
the initial decision node (square in Fig.  1). ‘Appropriate 
pharmacist care’ is an intermediate outcome measure for 
cost-effectiveness (a proxy for health gain) and is defined 
as “the provision of appropriate self-care, non-prescrip-
tion medicines and/or medical referral in line with the 
pre-agreed management pathway (HealthPathway) for 
each minor ailment” [32]. The terminal node represents 
the end point of the patient pathway whereby patients 
achieve symptom resolution or not within 14  days fol-
lowing the initial interaction with the pharmacist (tri-
angle in Fig. 1) [33]. This structure allows comparison of 
the expected costs and outcomes of the two alternative 
pathways. The difference in probabilities, costs and qual-
ity of life were generated to derive the total incremental 
impact of MAS, compared with UC, in a cohort who 
received: (i) appropriate pharmacist care and achieved 
symptom resolution; (ii) appropriate pharmacist care and 
did not achieve symptom resolution; (iii) pharmacist care 
outside of the agreed pathways and achieved symptom 
Self-care plus referral




































Fig. 1 Decision tree model structure. MAS minor ailment service, UC usual pharmacist care
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resolution, or (iv) pharmacist care outside of the agreed 
pathways but did not achieve symptom resolution.
The model was populated with probabilities and 
costs obtained from a cluster randomised controlled 
trial (cRCT) undertaken in Australia between July 2018 
and March 2019 (https ://www.anzct r.org.au identifier: 
ACTRN12618000286246) evaluating the effectiveness 
of MAS, compared to UC [34, 35]. Sites recruited were 
community pharmacies in the region covered by the pri-
mary health network (PHN) of Western Sydney [36] and 
were randomised using a computer-generated random 
number list (ratio of 1:1) in Microsoft Excel for Mac Ver-
sion 16.16.10. Eligible patients were recruited by a study 
pharmacist, from one of thirty pharmacies, if: (i) aged 
18 years or over; (ii) requesting or self-selecting a medi-
cine to treat symptoms (product-based presentation) 
and/or directly asking for pharmacists advice related to 
their symptoms (symptom-based presentation) for one 
of the following conditions: reflux, cough, common cold, 
headache (tension or migraine), primary dysmenorrhoea, 
and back pain; (iii) attending the pharmacy in person; (iv) 
able to provide consent; and (v) contactable by telephone. 
Patients received MAS or UC depending on allocation of 
the pharmacy to which they attended. Data in both arms 
was collected and managed using the Research Elec-
tronic Data Capture (REDCap) tool on provided iPads 
[37]. Pharmacists completed a data form for each patient. 
Patients were contacted at 14-days by phone to complete 
a follow-up questionnaire. Full details of the intervention 
and study protocol have been previously published [29, 
34, 35].
Intervention (MAS)
There were four features as part of the intervention which 
included:
(1) Standardised consultation
Patients received a face-to-face technology-based con-
sultation with a trained community pharmacist specific 
to their ailment. Pharmacists followed a number of steps 
in the patient encounter, including:
• Service offering, during which the pharmacist 
explained the features of the service.
• Clinical assessment, where the pharmacist elicited 
relevant clinical information and checked for referral 
symptoms.
• Standardised management, where the pharmacist 
utilised agreed pathways, which included the provi-
sion of self-care, non-prescription medicine(s) where 
appropriate, and/or referral to another healthcare 
provider.
• Documentation, where the pharmacist documented 
patient data in a data collection form. The pharmacist 
sent a direct massage to the patients’ GP with details 
of the consultation (with patient consent) using 
HealthLink [38].
To deliver the standardised consultation, MAS group 
pharmacists were provided with:
(1) Integrated technology platforms agreed with GPs
• HealthPathways [32]: Evidence-based pathways 
specific to each ailment. The research and writ-
ing of each pathway followed a literature review 
of international and national guidelines with lead-
ing GPs involved in the PHN governance. The 
pathways were used by pharmacists to guide their 
assessment and management during each consul-
tation.
• HealthLink [38]: A secure messaging system 
allowing bidirectional communication between 
the community pharmacist and the GP.
(2) Educational training program for pharmacists
Pharmacists delivering MAS were trained for 7.5-h by 
researchers and GPs at Western Sydney PHN. Training 
aimed to ensure pharmacists competency in delivering 
MAS, clinical areas, consultation skills, recognising red 
flags referral criteria, documentation processes and tech-
nology systems. The workshop involved a combination of 
lectures and interactive sessions.
(3) Practice change support for pharmacists
Pharmacists delivering MAS were provided 1-h 
monthly visits consisting of practice support and on-site 
training by a practice change facilitator (PCF). The PCF 
monitored data quality and intervention fidelity. PCFs 
were trained to ensure these objectives were met. PCFs 
addressed barriers to practice change using evidence-
based strategies and collected both quantitative and qual-
itative data.
Comparator (UC)
Patients attending the UC group of pharmacies received 
usual pharmacist care on presentation to the pharmacy. 
Pharmacists in the UC group did not receive any of the 
educational interventions outlined above including the 
support of a practice change facilitator. They attended 
a 2-h training workshop on data collection systems and 
recruitment at Western Sydney PHN.
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Model input parameters
Transition probabilities
Transition probabilities to the defined health states 
(Fig. 1) were directly derived from our cRCT study data, 
regardless of whether ‘appropriate pharmacist care’ was 
provided during the patient-pharmacist encounter. It 
was assumed that patients reporting partial resolution of 
symptoms at follow-up would achieve complete resolu-
tion given the self-limiting nature of minor ailment con-
ditions [39].
Costs
Costs were measured using cRCT trial data and val-
ued using local sources [29]. There were a number of 
costs identified and estimated. A pharmacists’ average 
hourly rate was sourced from the Pharmacy Industry 
Award [40] and was multiplied by the time consump-
tion to deliver MAS or UC. Costs of non-prescription 
medicines (paid for by the patient) were determined by 
averaging the price of medicines across three pharmacy 
groups including Chemist Warehouse, Amcal and Price-
line. Reconsultation and referral costs consisted of costs 
of contacts with other health care providers. Costs were 
included for patients who had: (i) adhered to pharmacist’s 
referral (adherence was established at follow-up by con-
firming whether the patient had reported visiting their 
healthcare provider within the 14-days following the 
consultation) or; (ii) reconsulted with a medical provider 
(reconsultation was established at follow-up for patients 
not referred by the pharmacist, but had reported seeking 
care from another health provider within 14-days follow-
ing the consultation). The average cost of a GP consulta-
tion was determined through examination of Medicare 
Benefits Schedule (MBS) reports. Referral adherence 
and reconsultation costs were calculated by considering 
the average cost per consult and patient out-of-pocket 
costs for all medicines (including non-prescription and 
prescription products). Prescription prices were deter-
mined using Pharmaceutical Benefits Scheme (PBS) and 
non-PBS prices for individual items and the total num-
ber of medicines per patient. A cost for training, technol-
ogy and facilitation was included for the MAS arm only. 
Training costs were included for the pharmacists who 
received MAS training. This was calculated by multiply-
ing the pharmacists’ average hourly rate by total training 
time. The costs of workshop facilitators and all training 
materials were incorporated. Costs for monthly visits to 
MAS pharmacies by the practice change facilitator were 
also included. A facilitation cost was determined by mul-
tiplying the hourly rate of the practice change facilitator, 
by the total number and duration of visits to MAS phar-
macies. Technology costs including an annual license 
cost per pharmacist for secure messaging software, were 
included. An estimated number of patients per phar-
macy, based on industry data, [41] was used to estimate 
the average cost ‘per patient’ for training, facilitation and 
technology.
Utilities
Utility values were not available from our cRCT study 
data, hence we relied on utility values reported in a 2015 
study (MINA study) conducted across two geographic 
regions in the UK (East Anglia, England and Gram-
pian, Scotland) [25]. The study was an observational 
study, with a prospective cohort design, carried out over 
a time horizon of 14-days. The aim of the study was to 
compare the effectiveness (patient outcomes) and cost-
effectiveness of care for selected minor ailments across a 
number of settings including community pharmacy, gen-
eral practice, and ED [25]. The study examined multiple 
clinical conditions including musculoskeletal aches and 
pains in arms, legs, back, hands and feet, eye discomfort, 
nausea, vomiting, diarrhoea, constipation, sore throat, 
cough, cold and sinus. Costs were estimated for the ini-
tial consultation and any actions taken in the following 
two-weeks for each minor ailment (including health care 
contacts, medication and investigations). To estimate the 
impact of the index consultation on health-related qual-
ity of life, participants were asked to complete the Euro-
QoL EQ-5D-3L at baseline and at 2-week follow-up [25] 
(Table 2).
The total accrued QALYs for each arm in the model 
were estimated by calculating the area under the curve 
(the time spent (14  days) in each health state (symp-
tom resolution or no symptom resolution), multiplied 
by the corresponding utility value). QALYs were con-
sidered an adequate outcome measure as it allows com-
parability across different diseases and interventions, 
provides a common metric for comparing cost per unit 
of health gain and the outcome measure recommended 
in Australia.
Results of the CUA are presented as the incremental 
cost-effectiveness ratio (ICER), calculated by dividing 
the difference in total accrued costs (incremental cost) 
by the difference in the total accrued QALYs (incre-
mental effect) [42]. The ICER was considered against a 
willingness-to-pay threshold. While Australia has not 
yet defined an explicit willingness-to-pay threshold, 




Mean utility (SD) Reference
Symptom resolution 0.91 (0.15) Refer to MINA study [25]
No symptom resolution 0.77 (0.22)
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a  base-case reference threshold of $28,033/QALY (95% 
CI $20,758–37,667) has been recommended [43].
Sensitivity analyses
Deterministic SA
A one-way deterministic SA was conducted to assess 
the impact of all known individual parameters tested 
independently, ceteris paribus, applying upper and 
lower limits owing to changes in assumptions made 
for the base-case analysis. The results for this analysis 
were summarised in a tornado diagram which shows 
the varying effects on the overall ICER. In addition, a 
multi-way SA was conducted to determine the impact 
of simultaneous changes to multiple parameters on 
the ICER. This was conducted to assess the extent the 
results may vary assuming a worst-case scenario analy-
sis. The worst-case scenario was defined as one with the 
highest possible patient-pharmacist consultation cost 
and assumes all patients adhere to referral recommen-
dations made by the pharmacist.
Probabilistic SA
A probabilistic SA was conducted by applying Monte 
Carlo simulation [44]. The model was made probabilis-
tic in order to account for joint parameter uncertainty. 
Individual parameters were assigned a parametric dis-
tribution, assuming a homogeneous sample of patients, 
to inform the parameter estimation (Table 3) [45]. The 
results were used to estimate the probability that MAS 
is cost-effective. The analysis was run in Microsoft 
Excel for Mac Version 16.16.10 software. The results 
are presented as a cost-effectiveness plane (scatter plot) 
and an acceptability curve.
Table 3 Parameters used to populate the economic model and distributions for uncertainty analysis
HEW higher education worker, MAS minor ailment service, MBS Medicare Benefits Schedule, PBS Pharmaceutical Benefits Scheme, PSA probabilistic sensitivity analysis, 
UC usual pharmacist care
a Lower and upper bound values represent 95% confidence interval; or upper and lower range from trial data
Health resource Mean 
model 
value




 Pharmacist rate (per hour) $29.37 $2.52 $24.04 $34.30 Australian Government Fair Work 
Ombudsman 2018 [40]
Gamma
 Time to deliver MAS (minutes per 
patient)
10.88 0.18 10.52 11.23 cRCT data [29] Normal
 Time to deliver UC (minutes per 
patient)
3.29 0.21 2.88 3.71 cRCT data [29] Normal
 Trainings with MAS (number per year) 1 0.51 0 2 cRCT data [29] Normal
 Facilitator rate with MAS (per hour) $46.28 $4.72 $37.02 $55.54 University of Technology Sydney award 
level HEW5 Step 1; cRCT data [29]
Gamma
 Facilitator visits with MAS (per month) 1 0.51 0 2 cRCT data [29] Normal
 Average training, facilitation and tech‑
nology cost with MAS (per patient)
$0.07 $0.02 $0.00 $0.11 Purchase invoices; cRCT data [29] Gamma
 Average nonprescription medicine 
price with MAS (per patient)
$10.62 $0.22 $10.20 $11.05 Amcal, Chemist Warehouse, Priceline 
2019 data; cRCT data [29]
Gamma
 Average nonprescription medicine 
price with UC (per patient)
$9.76 $0.20 $9.39 $10.14 Gamma
 Average cost of medicines at reconsult 
(per patient)
$9.79 $0.94 $7.94 $11.64 PBS 2019; Amcal, Chemist Warehouse, 
Priceline 2019 data; cRCT data [29]
Gamma
 General practitioner fee (per consult) $44.07 $6.74 $30.85 $57.29 MBS 2019 [46] Gamma
Probabilities
 Symptom resolution (MAS) 0.75 0.02 0.73 0.77 cRCT data [29] Beta
 Appropriate pharmacist care (MAS) 0.87 0.01 0.85 0.88 cRCT data [29] Beta
 Symptom resolution (UC) 0.74 0.02 0.65 0.69 cRCT data [29] Beta
 Appropriate pharmacist care (UC) 0.68 0.02 0.71 0.76 cRCT data [29] Beta
Utilities
 Symptom resolution 0.91 0.02 0.88 0.94 Refer to Watson study [25] Beta
 No symptom resolution 0.77 0.02 0.73 0.81 Beta
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Results
Eight hundred and ninety-four patients (n = 894) were 
recruited by thirty pharmacies (n = 30) in the cRCT. 
Eighty-two percent (n = 732) of patients were followed 
up at 2-weeks. Both effectiveness (patient outcomes) data 
and costs were available.
Model input parameters
Table 3 outlines the model input parameters and sources 
used to populate the economic model.
Table 4 shows a summary of the estimated mean costs 
for each cost category in both arms. The descriptive 
results show the primary difference in mean cost per 
patient arises from consultation time and referral adher-
ence (due to the higher referral rate and adherence to 
referral seen with MAS).
Economic analyses
Total cost and outcomes, along with incremental cost 
and incremental outcomes are shown in  Table  5.  On 
average, MAS was more expensive but also more effec-
tive compared to UC. With respect to the QALYs, 
patients (n = 524) receiving MAS gained an additional 
0.003 QALYs at an incremental cost of $7.14, compared 
to UC (n = 370). The results indicate an ICER of $2277 
(95% CI $681.49–3811.22) per QALY. For the clinical 
effect measure of appropriate pharmacist care, the ser-
vice resulted in an incremental score of 0.191 additional 
patients receiving appropriate pharmacist care, rela-
tive to UC, resulting in an ICER of $37.42 per additional 
episode of appropriate pharmacist care. For the clinical 
effect measure of symptom resolution, MAS resulted in 
an incremental score of 0.012 additional patients achiev-
ing symptom resolution, relative to UC, resulting in  an 




The tornado graph displays bars for each parameter 
depicting which variables (greatest to smallest) impacts 
the estimated mean ICER (Fig. 2). The variable with the 
greatest impact on the ICER result was the probability 
of MAS patients receiving pharmacist care outside the 
agreed pathways and achieving symptom resolution. 
The mean number of medicines supplied during a MAS 
consultation was the variable with the second greatest 
impact on results. The impact on the ICER was almost 
null when the parameters of training costs and the aver-
age duration of consultation were changed.
The results of the multi-way SA are found in Table 6.
Probabilistic SA
The results of 5000 simulations were found to produce 
stable results and are presented in a cost-effectiveness 
plane (scatter plot) (Fig. 3). Each iteration (point on the 
graph) represents an incremental cost and incremental 
Table 4 Estimated mean cost of MAS and UC
AUD Australian dollars, MAS minor ailment service, UC usual pharmacist care
Mean cost per patient 
($AUD)a
MAS UC
Consultation time 5.33 1.61
Non‑prescription medicine 10.85 10.36
Referral adherence (including medicines) 5.59 0.61
Reconsultation (incl. medicines) 7.73 9.70
Training, facilitation, technology set‑up 0.07 –
Total cost (SD) 29.56 (4.21) 22.28 (4.59)
Table 5 Incremental analysis: Cost-utility (base case) and cost-effectiveness results
AUD Australian dollars, ICER incremental cost effectiveness ratio, MAS minor ailment service, QALY quality adjusted life year, UC usual pharmacist care
The costs used in the cost utility and cost effectiveness evaluations for MAS is $26.88 rather than $29.56 as a result of the decision tree modelled analysis that 
considers the proportion of patients in each arm receiving an outcome instead of the mean costs stated above. Similarly, UC is $19.75 instead of $22.28




 UC $19.75 (SD $7.47) 0.0264
 MAS $26.88 (SD $7.62) 0.0296 $7.14 0.003 $2277
Outcome = episode of appropriate pharmacist care (care meeting agreed treatment pathways)
 UC $19.75 (SD $7.47) 0.676
 MAS $26.88 (SD $7.62) 0.866 $7.14 0.191 $37.42
Outcome = extra patient achieving symptom resolution
 UC $19.75 (SD $7.47) 0.738
 MAS $26.88 (SD $7.62) 0.750 $7.14 0.012 $586.88
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benefit when model parameters take random values 
from a pre-specified range and probability distributions 
(full details of the analysis are provided in Additional 
file 1). The area to the right of the vertical axis is clini-
cally beneficial, while the area above the horizontal axis 
is cost-increasing. Therefore, iterations are primarily in 
the north-east quadrant of the plane, reiterating MAS 
is more costly and more effective, than UC.
The probability of MAS being cost-effective for a 
range of willingness-to-pay thresholds is presented in 
a cost-effectiveness acceptability curve (CEAC) (Fig. 4). 
The CEAC shows that MAS has a probability of being 
cost-effective from 9% at a willingness-to-pay of $1000 
per QALY to 100% at a willingness to pay of $6000 per 
QALY, compared with UC. The probability that the 
intervention was cost-effective at the recommended 
threshold of $28,033 per QALY was 100%.
Discussion
MAS has already proven clinical effectiveness when com-
pared to current usual practice in Australian community 
pharmacies [34, 35]. This study provides details of a CUA 
evaluating MAS compared to UC, which was undertaken 
from a societal perspective. The robustness of results 
and uncertainty in model parameters was addressed by 
conducting a series of sensitivity analyses. The results 
indicate an ICER of $2277 (95% CI 681.49–3811.22) per 
QALY indicating higher costs and QALYs with MAS 
compared to UC. Based on a reference threshold of 
$28,033/QALY, findings suggest that implementation 
of MAS in Australian community pharmacies is a value 
for money intervention. The results presented should be 
interpreted and compared to ICERs from previous stud-
ies of health services that were accepted (or not) at clini-
cal and policy levels within the Australian setting [47].
Comparison to international literature
A number of countries have adopted MAS models. How-
ever, the international literature primarily provides com-
parison of pharmacy based minor ailment care to other 
health settings, such as general practice and ED. These 
studies suggest that the implementation of MASs leads 
 Probability of MAS patients receiving care outside agreed pathways & achieving SR
Mean number of non-prescription medicines supplied during MAS consult
Mean number of non-prescription medicines supplied during UC
Number of medicines provided during reconsultation for UC patients
 Probability of UC patients receiving appropriate care & achieving SR
 Probability of MAS patients receiving appropriate care & achieving SR
 Probability of UC patients receiving care outside agreed pathways & achieving SR
Pharmacist hourly rate
Mean non-prescription out-of-pocket medicine cost per MAS patient
Cost of general practitioner consultation
Mean out-of-pocket non-prescription medicine cost per UC patient
Utility: SR
Pharmacists time to deliver UC
Pharmacists time to deliver MAS
Utility: no SR
ICER (AUD/QALY)
BASE CASE ICER: $2,277/ QALY
Fig. 2 ICER tornado diagram for multiple one‑way SA. AUD Australian dollars, ICER incremental cost effectiveness ratio, MAS minor ailment service, 
QALY quality adjusted life year, SR symptom resolution, UC usual pharmacist care. Grey indicates a lower value for each variable was applied. Blue 
indicates a higher value for each variable was applied. Red indicates the base case ICER value
Table 6 Multi-way sensitivity analysis
AUD Australian dollars, ICER incremental cost effectiveness ratio, MAS minor 
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Fig. 3 Cost effectiveness plane for MAS over UC. AUD Australian dollars, ICER incremental cost effectiveness ratio, MAS minor ailment service, QALY 



























Fig. 4 Cost effectiveness acceptability curve showing the probability of MAS being cost‑effective at different willingness‑to‑pay thresholds. AUD 
Australian dollars, ICER incremental cost effectiveness ratio, QALY quality adjusted life year
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to more efficient use of GP and ED services and overall 
health spending [48–53]. In the UK, Watson et al., esti-
mated the cost and effectiveness (patient health out-
comes) of pharmacy-based care for minor ailments 
compared with care provided by general practitioners 
or in ED settings [25]. Mean overall costs per consulta-
tion were £29.30 for pharmacy-based care compared 
with general practice (£82.34) and ED (£147.09) [25]. 
Pharmacy-based care for minor ailments was estimated 
to be less costly and as effective (in terms of symptom 
resolution) compared with ED and general practice [25]. 
Authors concluded that pharmacy-based minor ailment 
care was the dominate option [25]. Similarly in Canada, 
Rafferty et  al. conducted an economic impact analysis 
measuring costs of a minor ailment program and the 
alternative scenario of UC, using primary data on phar-
macists’ prescribing consultations in Saskatchewan [16]. 
After 5 years of implementation, cumulative cost savings 
were projected to be $3482,660 Canadian dollars (CAD), 
from a societal perspective. The study identified the cost 
to deliver the service at $18/consult (CAD), when com-
pared with the cost of a GP consultation ($66.40 CAD) 
or an ED visit ($138 CAD) [16]. Comparatively, our 
study findings revealed a mean cost per MAS consult to 
be $29.56 AUD, compared to $22.28 for a pharmacist to 
conduct UC. Though, the variability in conditions con-
sidered as minor ailments in the literature represents a 
challenge for comparison of our results and data inter-
pretation [54]. Studies identified in the international lit-
erature do not use a randomised trial study design, utilise 
comparators other than usual care, and in some instances 
do not specify the member of staff involved in providing 
management. Future research for MASs implemented 
within international health systems would be valuable. 
This should include clinical and economic data with a 
comparator of usual care.
Strengths and limitations
There are some limitations to our study. While the deci-
sion tree model is a step forward in mapping minor 
ailment interactions and their implications, it is a simpli-
fication of reality and is subject to the trade-offs between 
data availability and assumptions made in construct-
ing the model. We treated our study population as a 
full cohort and have assumed patients lost to follow-up 
behave similarly (i.e. similar probability of adhering to 
referral advice or reconsulting within 14 days) and their 
health status resolves (i.e. similar probability of achiev-
ing symptom resolution) in a similar way to patients 
followed-up. Our cRCT study was powered to detect 
changes in the outcome of ‘appropriate pharmacist care’ 
and this was assumed to lead to changes in symptom res-
olution. By definition, a minor ailment is self-limiting and 
involves symptom resolution regardless of pharmacist (or 
medical) intervention. Given symptom resolution prob-
abilities were incorporated into the model, this impacts 
the results of our economic evaluation. While we saw a 
positive effect on resolution rates with MAS, the differ-
ences in symptom resolution were small compared with 
UC (RR 1.06; 95% CI 1 to 1.13; p = 0.035 [29]). This is 
reflected in an additional sensitivity analysis undertaken 
whereby MAS resulted in an ICER of $586.88 per extra 
patient achieving symptom resolution.
A time horizon of 14-days was considered appropri-
ate to account for costs and health outcomes for the 
conditions evaluated (e.g. the common cold would nor-
mally resolve in 7–10  days). A 14-day time horizon has 
been previously applied in international studies assessing 
minor ailments and symptom resolution rates [25]. The 
timeframe was also chosen by researchers to reduce the 
possibility of recall bias [30]. It is important to acknowl-
edge that conditions such as migraine, low back pain, 
reflux and dysmenorrhoea may be episodic or self-limit-
ing, however also may be recurrent or chronic in nature. 
Methodological issues regarding time will have implica-
tions when evaluating the cost-effectiveness of healthcare 
services [55]. Analyses with shorter time horizons poten-
tially omit relevant outcomes and therefore may provide 
incorrect results [55].
Utility values were not available from our cRCT study 
data, hence we relied on utility values reported in pub-
lished literature [25]. The transferability of utility scores 
between jurisdictions remains unclear and the utility 
weights applied may not represent Australian prefer-
ences. A literature review by Knies et  al. [56] discussed 
the international transferability of utilities derived from 
EQ-5D questionnaires. The authors found differences 
between national EQ-5D value sets and discouraged 
the application of utilities from other countries [56]. 
Although this is acknowledged as an important limita-
tion, the use of literature estimates was considered the 
best available evidence to conduct the CUA. Further-
more, the use of QALYs to capture health benefits in a 
short time horizon (14 days) is also contentious and poses 
challenges when interpreting results. However, the use of 
QALYs were considered appropriate mainly because they 
provide a common metric for comparing cost per unit 
of health gain and this is currently the outcome measure 
recommended in Australia. It was not possible to capture 
the likely gradual increment in QALY as we didn’t have 
trial or published data to rely on. The impact of assuming 
a direct QALY gain is that the total accrued QALYs may 
be slightly overestimated. Though, because this assump-
tion is occurring in both arms, it is unlikely to impact 
overall results. We attempted to improve the transferabil-
ity of results to wider Australia using nationally reported 
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unit costs and accounted for potential variation in costs 
through SA.
Local variation in practice, for example referral rates 
to general practice, can greatly influence the cost of pro-
viding MAS. This was evidenced in our clinical evalua-
tion findings [29] which identified that MAS pharmacists 
referred four times as many patients when using the 
agreed clinical pathways, compared with UC. The high 
referral rate was a result of patients identified to be self-
medicating or experiencing symptoms for prolonged 
periods without assessment or re-assessment by a medi-
cal practitioner [29]. Furthermore, patients receiving 
MAS were five times more likely to follow through with 
referrals made by the pharmacist during the consultation, 
compared to current practice [29].
The extent of transferability of findings is dependent on 
the context of design and implementation. A methodo-
logical consideration is the urban Australian community 
pharmacy setting this study was conducted. Future stud-
ies to confirm or enhance implementation of MAS in 
other contexts would help address these limitations. Fur-
thermore, refining the decision tree model by addressing 
some of its limitations or confirming transition probabili-
ties in future evaluations would be useful to validate the 
economic findings in this study.
Implications for policy and practice
This research was conceived and undertaken at a time 
of change to the health landscape in Australia [57]. The 
Australian health system is faced with challenges of 
improving accessibility and quality of care in the face of 
constrained funding [57]. Policy makers, at governmental 
and organisational levels, are increasingly interested in 
cost-effective, evidence-based, patient-centered services. 
The drivers of this interest are equally to save the health 
system money, improve patient outcomes and quality use 
of medicines.
Australian primary care will need to undergo reforms 
that incentivise pharmacists to deliver self-care effec-
tively. International models of community pharmacy care 
exist that attempt to address these challenges. Scotland, 
for example, uses a capitation model of remuneration and 
provides pharmacists with the responsibility for the care 
of individual patients registered to that pharmacy [58].
It is recommended that due consideration be given 
for community pharmacies nationwide to adopt and 
implement MAS. There should be a focus on upskill-
ing community pharmacists to deliver MAS in an inte-
grated and coordinated capacity. Policy and funding 
alignment will also be a major determinant for future 
sustainability. Expanding community pharmacists’ 
scope through training, as seen in the UK and Can-
ada, for other clinical areas such as minor abrasions, 
wounds, strains and sprains, minor burns etc. or pre-
scribing of certain prescription medicines within a col-
laborative model for certain conditions is likely to add 
further economic benefits.
Conclusion
There is significant potential to amplify self-care and 
responsible self-medication in Australia. With national 
implementation in the Australian health system there 
is potential for system efficiency gains, demonstrated 
through delivering health care that is optimally cost-
efficient and clinically effective at an appropriate level, 
and working collaboratively within an integrated system. 
The implicit assumption is that patients consulting GPs 
or EDs for these conditions could be reduced by transfer-
ring patients, where appropriate, to the community phar-
macy setting with the aim of fully utilising primary health 
locations and professionals in Australia.
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